The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 301–400 of 1,005
Puchchakayala, G. R., Akina, S., & Thati, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/974013 · Cited by 171
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Role of Vitamin E in the Treatment of Alzheimer’s Disease: Evidence from Animal Models
Gugliandolo, A., Bramanti, P., & Mazzon, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122504 · Cited by 170
In vitro antioxidant activity of non‐cultivated vegetables of ethnic Albanians in southern Italy
Pieroni, A., Janiak, V., Dürr, C. M., Lüdeke, S., Trachsel, E., & Heinrich, M. (2002) · Phytotherapy Research · doi:10.1002/ptr.1243 · Cited by 170
Risk Factors for Nursing Home Placement in a Population‐Based Dementia Cohort
Smith, G. E., Kokmen, E., & OʼBrien, P. C. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04998.x · Cited by 170
Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 169
Dietary approaches that delay age-related diseases
Everitt, A. V., Hilmer, S. N., Brand-Miller, J. C., Jamieson, H. A., Truswell, A. S., Sharma, A. P., Mason, R. S., Morris, B. J., & Couteur, D. G. L. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.1.11 · Cited by 168
Antioxidants: New-generation therapeutic base for treatment of polygenic disorders
Tiwari, A. K. (2004) · Cited by 166
The Effectiveness of Vitamin E Treatment in Alzheimer’s Disease
Lloret, A., Esteve, D., Monllor, P., Cervera‐Ferri, A., & Lloret, Á. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040879 · Cited by 165
Protein S -Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases
Nakamura, T., & Lipton, S. A. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.002 · Cited by 164
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162
Selegiline for Alzheimer's disease
Birks, J., & Flicker, L. A. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000442 · Cited by 162
Sikkes, S. A. M., Tang, Y., Jutten, R. J., Wesselman, L. M. P., Turkstra, L. S., Brodaty, H., Clare, L., Cassidy‐Eagle, E. L., Cox, K. L., Chételat, G., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12188 · Cited by 162
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease
Perry, N. S. L., Houghton, P. J., Sampson, J., Theobald, A. E., Hart, S., Lis‐Balchin, M., Hoult, J. R. S., Evans, P., Jenner, P. G., Milligan, S. R., et al. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011777846 · Cited by 161
Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice
Quinn, J. F., Bussiere, J. R., Hammond, R., Montine, T. J., Henson, E., Jones, R. E., & Stackman, R. W. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.014 · Cited by 161
Down syndrome and Alzheimer's disease: A link between development and aging
Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 161
ALZHEIMER'S DISEASE AND RELATED DISORDERS
Raskind, M. A., & Peskind, E. R. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70341-2 · Cited by 161
Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
Galasko, D. R., Schmitt, F. A., Thomas, R. G., Jin, S., Bennett, D., & Ferris, S. H. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050502 · Cited by 160
Self-citationAntioxidant Therapy in Alzheimers Disease: Theory and Practice
Aliev, G., Obrenovich, M. E., Reddy, V. P., Shenk, J. C., Moreira, P. I., Nunomura, A., Zhu, X., Smith, M. A., & Perry, G. L. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369582 · Cited by 160
Monoamine oxidase and tobacco dependence
Lewis, A., Miller, J. H., & Lea, R. A. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.05.019 · Cited by 159
Cummings, J. L., McRae, T. D., & Zhang, R. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221293.91312.d3 · Cited by 160
Vitamin E regulates mitochondrial hydrogen peroxide generation
Chow, C. K., Ibrahim, W. H., Wei, Z., & Chan, A. C. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00121-5 · Cited by 158
Drug Treatment Effects on Disease Progression
Chan, P., & Holford, N. H. G. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.625 · Cited by 158
Kidd, P. M. (2008) · PubMed · Cited by 158
Burns, A. S., & O'Brien, J. T. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068299 · Cited by 157
Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
Self-citationStorr, T., Merkel, M., Song-Zhao, G. X., Scott, L. E., Green, D. E., Bowen, M. L., Thompson, K. H., Patrick, B. O., Schugar, H. J., & Orvig, C. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068965r · Cited by 156
Vitamin E beyond Its Antioxidant Label
Ungurianu, A., Zanfirescu, A., Nițulescu, G., & Margina, D. M. (2021) · Antioxidants · doi:10.3390/antiox10050634 · Cited by 156
Clinical trials in mild cognitive impairment: lessons for the future
Jelić, V. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072926 · Cited by 156
Alzheimer's Disease: A Lesson from Mitochondrial Dysfunction
Moreira, P. I., Santos, M. S., & Oliveira, C. R. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1703 · Cited by 155
Ferreiro, E. B., Baldeiras, I., Ferreira, I. L., Costa, R. O., Rego, A. C., Pereira, C., & Oliveira, C. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/735206 · Cited by 156
Huang, L., Lu, C., Sun, Y., Mao, F., Luo, Z., Su, T., Jiang, H., Shan, W., & Li, X. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300978h · Cited by 154
Dietary enrichment counteracts age-associated cognitive dysfunction in canines
Milgram, N. W., Zicker, S. C., Head, E., Muggenburg, B. A., Murphey, H. L., Ikeda-Douglas, C. J., & Cotman, C. W. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00020-9 · Cited by 154
Self-citationBiological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 154
Xiao, X., Zhang, H., & Tang, X. C. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10075 · Cited by 154
Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
Swerdlow, R. H. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.021 · Cited by 154
Schachter, A. S., & Davis, K. L. (2000) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2000.2.2/asschachter · Cited by 153
Why Pleiotropic Interventions are Needed for Alzheimer's Disease
Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 152
Jeong, E. J., Lee, K. Y., Kim, S. H., Sung, S. H., & Kim, Y. C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.015 · Cited by 151
Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions
Lynch, T. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00112-1 · Cited by 151
Characterization of risk factors for vascular dementia
Ross, G. W., Petrovitch, H., White, L. R., Masaki, K., Li, C. Y., Curb, J. D., Yano, K., Rodríguez, B. L., Foley, D. J., Blanchette, P. L., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.337 · Cited by 151
Lipid peroxidation in neurodegeneration: new insights into Alzheimerʼs disease
Arlt, S., Beisiegel†, U., & Kontush, A. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200206000-00009 · Cited by 151
Drew, K. L., Rice, M. E., Kuhn, T. B., & Smith, M. A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00628-1 · Cited by 150
The Mitochondrial Spiral: An Adequate Cause of Dementia in the Alzheimer's Syndrome
Blass, J. P. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05576.x · Cited by 150
Cognitive Function of Children With Cystic Fibrosis: Deleterious Effect of Early Malnutrition
Koscik, R. L., Farrell, P. M., Kosorok, M. R., Zaremba, K. M., Laxova, A., Lai, H.-C., Douglas, J. A., Rock, M. J., & Splaingard, M. (2004) · PEDIATRICS · doi:10.1542/peds.113.6.1549 · Cited by 150
Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease
Moore, A. H., & O’Banion, M. K. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00162-x · Cited by 150
Youdim, M. B. H., & Weinstock, M. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015131516649 · Cited by 150
The Role of Oxidative Stress in Amyotrophic Lateral Sclerosis and Parkinson’s Disease
Baillet, A. C., Chanteperdrix, V., Trocmé, C., Casez, P., Garrel, C., & Besson, G. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0212-5 · Cited by 149
Mocchegiani, E., Costarelli, L., Giacconi, R., Malavolta, M., Basso, A., Piacenza, F., Ostan, R., Cevenini, E., Gonos, E. S., Franceschi, C., et al. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.001 · Cited by 149
Yeung, A. W. K., Georgieva, M. G., Atanasov, A. G., & Tzvetkov, N. T. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00143 · Cited by 149
Elevated oxidative stress in models of normal brain aging and Alzheimer's disease
Butterfield, D. A., Howard, B. J., Yatin, S. M., Koppal, T., Drake, J., Hensley, K., Aksenov, M. Y., Aksenova, M. V., Subramaniam, R., Varadarajan, S., et al. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00442-7 · Cited by 149
Impact of antioxidants, zinc, and copper on cognition in the elderly
Age-Related Eye Disease Study Research Group (2004) · Neurology · doi:10.1212/01.wnl.0000142969.19465.8f · Cited by 149
Sagare, A. P., Deane, R., & Zloković, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 150
Liu, G., Liu, X., Cai, Z., Jiao, G., Xu, G., & Tang, W. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201300646 · Cited by 148
Farber, N. B., Newcomer, J. W., & Olney, J. W. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)60453-7 · Cited by 148
Pharmacotherapeutic approaches to the treatment of Alzheimer's disease
Standridge, J. B. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90064-1 · Cited by 148
Youdim, K. A., Shukitt‐Hale, B., Martin-Marco, A., Wang, H., Denisova, N., Bickford, P. C., & Joseph, J. A. (2000) · Nutritional Neuroscience · doi:10.1080/1028415x.2000.11747338 · Cited by 148
Milgram, N. W., Head, E., Zicker, S. C., Ikeda-Douglas, C. J., Murphey, H. L., Muggenberg, B. A., Siwak, C. T., Tapp, P. D., Lowry, S. R., & Cotman, C. W. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.01.007 · Cited by 147
Self-citationAltered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia
Sinclair, A. J., Bayer, A. J., Johnston, J., Warner, C. A., & Maxwell, S. R. J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(1998120)13:12 · Cited by 147
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 147
THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE
Selkoe, D. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70232-2 · Cited by 146
Chang, Y., Chang, W., Tsai, N., Huang, C., Kung, C., Su, Y., Lin, W.-C., Cheng, B., Su, C.-M., Chiang, Y.-F., et al. (2014) · BioMed Research International · doi:10.1155/2014/182303 · Cited by 145
Gemma, C., Mesches, M. H., Sepesi, B., Choo, K., Holmes, D. B., & Bickford, P. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-14-06114.2002 · Cited by 143
Osella, M. C., Re, G., Odore, R., Girardi, C., Badino, P., Barbero, R., & Bergamasco, L. (2006) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2006.11.007 · Cited by 143
Behavior Problems in Geriatric Pets
Landsberg, G. M., & Araujo, J. A. (2005) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2004.12.008 · Cited by 143
Viña, J. (2004) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2004.02.013 · Cited by 143
Current Concepts in the Pathogenesis of Alzheimer’s Disease
Carr, D. B., Goate, A., Phil, D., & Morris, J. C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00262-3 · Cited by 143
Jayaprakasam, B., Padmanabhan, K., & Nair, M. G. (2010) · Phytotherapy Research · doi:10.1002/ptr.3033 · Cited by 142
Becker, R. E., Greig, N. H., & Giacobini, E. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15213 · Cited by 143
Re, F., Airoldi, C., Zona, C., Masserini, M., Ferla, B. L., Quattrocchi, N., & Nicotra, F. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791959729 · Cited by 142
Non-Cholinergic Strategies for Treating and Preventing Alzheimer??s Disease
Doraiswamy, P. M. (2002) · CNS Drugs · doi:10.2165/00023210-200216120-00003 · Cited by 142
Mohajeri, M. H., Troesch, B., & Weber, P. (2015) · Nutrition · doi:10.1016/j.nut.2014.06.016 · Cited by 141
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 141
Kupsch, A. R., Sautter, J., Götz, M. E., Breithaupt, W., Schwarz, J., Youdim, M. B. H., Riederer, P. F., Gerlach, M., & Oertel, W. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170018 · Cited by 141
Nutrition and cognitive impairment in the elderly
González‐Gross, M., Marcos, A., & Pietrzik, K. F. (2001) · British Journal Of Nutrition · doi:10.1079/bjn2001388 · Cited by 141
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 140
Oxidative Damage and Cognitive Dysfunction: Antioxidant Treatments to Promote Healthy Brain Aging
Head, E. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9808-4 · Cited by 140
Prospects for Pharmacological Intervention in Alzheimer Disease
Emilien, G., Beyreuther, K. T., Masters, C. L., & Maloteaux, J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.4.454 · Cited by 140
Hăncianu, M., Cioancă, O., Mihăşan, M., & Hriţcu, L. (2013) · Phytomedicine · doi:10.1016/j.phymed.2012.12.005 · Cited by 139
Osakada, F., Hashino, A., Kume, T., Katsuki, H., Kaneko, S., & Akaike, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.029 · Cited by 139
Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Clark, C. M., & Karlawish, J. H. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00010 · Cited by 139
Validity of clinical criteria for the diagnosis of dementia with Lewy bodies
Verghese, J., Crystal, H., Dickson, D. W., & Lipton, R. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1974 · Cited by 139
Antioxidant Therapy in Neurologic Disease
Delanty, N., & Dichter, M. A. (2000) · Archives of Neurology · doi:10.1001/archneur.57.9.1265 · Cited by 137
Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Albert, C. M., & Grodstein, F. (2009) · Circulation · doi:10.1161/circulationaha.108.816900 · Cited by 136
Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation
Lott, I. T., Doran, E., Nguyen, V. Q., Tournay, A., Head, E., & Gillen, D. L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34114 · Cited by 136
Oxidant/antioxidant imbalance and the risk of Alzheimer's disease
Moneim, A. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150325182702 · Cited by 136
Vitamin E and neurodegeneration
Ulatowski, L. M., & Manor, D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.002 · Cited by 136
The role of oxidative damage in mitochondria during aging: a review
Huang, H. (2004) · Frontiers in bioscience · doi:10.2741/1298 · Cited by 136
Pathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 137
Predictors of mortality in patients with Alzheimer's disease living in nursing homes
Gambassi, G., Landi, F., Lapane, K. L., Sgadari, A., Mor, V., & Bernabei, R. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.1.59 · Cited by 136
Causes of Alzheimer's disease.
Muñoz, D. G., & Feldman, H. (2000) · PubMed Central · Cited by 136
Antioxidants halt axonal degeneration in a mouse model of X‐adrenoleukodystrophy
López‐Erauskin, J., Fourcade, S., Galino, J., Ruíz, M., Schlüter, A., Naudí, A., Jové, M., Portero‐Otín, M., Pamplona, R., Ferrer, I., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22363 · Cited by 135
Luchsinger, J. A., Noble, J. M., & Scarmeas, N. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0057-8 · Cited by 135
Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Casetta, I., Govoni, V., & Granieri, E. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054065729 · Cited by 135
Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome
Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro
Ono, K., Yoshiike, Y., Takashima, A., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.035 · Cited by 134
The female sex hormone oestrogen as a neuroprotectant
Behl, C., & Holsboer, F. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01392-9 · Cited by 134
de Diego-Otero, Y., Romero-Zerbo, Y., Bekay, R. E., Decara, J., Sanchez, L., Fonseca, F. R.-D., & Arco-Herrera, I. D. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.152 · Cited by 133
Glucose metabolism and Alzheimer's disease
Schubert, D. A. (2005) · Ageing Research Reviews · doi:10.1016/j.arr.2005.02.003 · Cited by 133
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
